Emergent BioSolutions Secures Contract Modification Valued at Approximately $52.7 Million for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government

Emergent BioSolutions (NYSE:EBS) received a $52.7 million contract modification from ASPR/HHS to supply ACAM2000® smallpox and mpox vaccine, ancillaries, and diluent replacement lots for U.S. preparedness.

Rhea-AI Summary

Emergent BioSolutions (NYSE:EBS) received a $52.7 million contract modification from ASPR/HHS to supply ACAM2000® smallpox and mpox vaccine, ancillaries, and diluent replacement lots for U.S. preparedness. Deliveries are expected to begin in June 2026 under an existing 10-year contract.

The announcement follows recent approvals of ACAM2000® for high-risk adults in Saudi Arabia and an expanded mpox indication in Singapore. The release also reiterates ACAM2000®’s indication and detailed safety information, including boxed warnings and common adverse reactions.

Positive

• Award of $52.7 million ACAM2000® contract modification from ASPR/HHS
• Deliveries under the contract expected to begin in June 2026
• Contract falls under an existing 10-year ASPR agreement (75A50119C00071)
• Recent ACAM2000® approval in Saudi Arabia for high-risk smallpox and mpox use
• Expanded ACAM2000® mpox indication approved in Singapore for high-risk adults

Negative

• Serious complications warning, including myocarditis and pericarditis at 5.7 per 1000 primary vaccinees
• ACAM2000® contraindicated in individuals with severe immunodeficiency
• Live vaccinia virus vaccine can be transmitted to close contacts of vaccinees

Argus Jun 29 session

-0.82% close to close Open Argus

Details

News Market Reaction – EBS

On Jun 29, the day this news came out, EBS closed 0.82% below the previous close.

Data tracked by StockTitan Argus for the Jun 29 session.

Key Figures

Contract value: $52.7 million Contract term: 10-year contract Myocarditis/pericarditis rate: 5.7 per 1000 primary vaccinees +5 more

Contract value

$52.7 million

ACAM2000 contract modification from ASPR/HHS

Contract term

10-year contract

Existing ASPR agreement (75A50119C00071)

Myocarditis/pericarditis rate

5.7 per 1000 primary vaccinees

Suspect myocarditis and pericarditis cases after ACAM2000

Myocarditis/pericarditis CI lower

1.9 per 1000

95% confidence interval lower bound for myocarditis/pericarditis

Myocarditis/pericarditis CI upper

13.3 per 1000

95% confidence interval upper bound for myocarditis/pericarditis

VAERS phone

1-800-822-7967

Reporting suspected adverse reactions

Emergent US phone

1-877-246-8472

Reporting suspected adverse reactions to Emergent BioSolutions

Emergent Canada phone

1-800-768-2304

Reporting suspected adverse reactions in Canada

Historical Context

5 past events · Latest: May 28

5 events

1. May 28

   Government contract

   24h Move

   -0.7%

   ASPR contract modification for BAT botulism antitoxin under 10-year agreement.

2. May 20

   Investor conferences

   24h Move

   +3.1%

   Management participation in multiple late-May and early-June investor conferences.

3. May 18

   Regulatory approval

   24h Move

   +2.4%

   Saudi Food and Drug Authority approval of ACAM2000 for high‑risk individuals.

4. Apr 30

   Earnings report

   24h Move

   +2.9%

   Q1 2026 results with revenue, net income, refinancing and new contracts.

5. Apr 30

   Label expansion

   24h Move

   +3.0%

   Singapore approval expanding ACAM2000 indication to include mpox prevention.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

myocarditis, pericarditis, encephalomyelitis, stevens-johnson syndrome, +2 more

6 terms

myocarditis medical

"Myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000"

Inflammation of the heart muscle that can weaken the heart’s ability to pump and cause symptoms such as chest pain, shortness of breath, or abnormal heart rhythms. Investors care because myocarditis can affect healthcare costs, clinical trial outcomes, regulatory decisions, product safety perceptions, workforce availability, or lead to legal and reputational risks for companies, similar to how a car engine problem can halt a business until it's fixed.

pericarditis medical

"Myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000"

Pericarditis is inflammation of the thin sac that surrounds the heart, like irritation of a protective sleeve or a balloon around the organ. It can cause chest pain, fatigue and other symptoms and is important to investors because cases linked to a drug, vaccine or medical device can change regulatory decisions, affect sales and trigger safety reviews or legal risk, which can move a company’s stock and future outlook.

encephalomyelitis medical

"encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia"

Encephalomyelitis is inflammation of the brain and spinal cord that can be caused by infections, autoimmune reactions, or other triggers; think of it as swelling that disrupts the body’s central processing and wiring. It matters to investors because the condition can drive demand for diagnostics, treatments, and clinical trials, affect regulatory reviews and healthcare costs, and influence the valuation of companies developing relevant therapies or tests.

stevens-johnson syndrome medical

"erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum"

A rare but serious medical condition where the skin and mucous membranes blister and peel away, similar to a severe burn that affects large areas of the body and often requires hospital care. For investors it matters because it is a known, sometimes drug-triggered safety issue that can halt clinical trials, prompt regulatory warnings or recalls, and lead to large legal and financial consequences for companies producing implicated medicines or devices.

eczema vaccinatum medical

"erythema multiforme major (including Stevens-Johnson syndrome), eczema vaccinatum resulting"

A rare but serious skin infection caused when the live vaccinia virus (used in some smallpox vaccines) spreads in people with eczema or similar skin conditions, producing widespread, painful lesions. Think of it as an allergic wildfire on the skin triggered by a live vaccine virus. Investors care because occurrence affects vaccine safety profiles, regulatory approval, liability risk, and public acceptance—factors that can change a developer’s market value and product demand.

ocular vaccinia medical

"accidental eye infection (ocular vaccinia) which can cause ocular complications"

An eye infection caused by the live vaccinia virus used in some smallpox vaccines or vaccine candidates; it occurs when the vaccine virus unintentionally reaches the eye and causes inflammation, corneal injury, pain and sometimes lasting vision impairment. Investors should care because ocular vaccinia is a safety signal that can prompt clinical‑trial pauses, regulatory scrutiny, product recalls or lawsuits—effects that can delay approvals, harm sales and damage a developer’s reputation, much like a manufacturing defect that forces a recall.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued at $52.7 million from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services to supply ACAM2000^® (Smallpox and Mpox (Vaccinia) Vaccine, Live) vaccine, ancillaries as well as diluent replacement lots for smallpox preparedness and response needs. Deliveries are expected to begin this month.

“This new contract modification for ACAM2000^® underscores the U.S. government’s continued focus on biodefense preparedness and reflects Emergent’s longstanding role to collaborate and help protect civilians and warfighters against potential smallpox and mpox threats,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “In this increasingly dangerous world, we are proud to continue supporting the U.S. government as they continue to take critical, proactive steps on biodefense preparedness.”

This award follows Emergent’s recent announcements that the Saudi Food and Drug Authority has approved ACAM2000® for immunization against smallpox and mpox in high-risk individuals and that Singapore’s Health Sciences Authority has approved an expanded indication for ACAM2000^® to include prevention of mpox disease in adults determined to be at high risk for mpox infection.

Experts consider smallpox to be a credible bioterror threat,  with potential health, economic and national security implications due to its mortality rate.¹  Emergent specializes in developing, manufacturing and delivering medical countermeasures to the U.S. government and allies around the world to support health preparedness and help protect the public from potential threats like smallpox, mpox, Ebola, anthrax and botulism.

This contract modification is under Emergent’s existing 10-year contract (75A50119C00071) with ASPR.

Indication and Select Important Safety Information for ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live)
Indication
ACAM2000® is indicated for active immunization for the prevention of smallpox and mpox disease in individuals determined to be at high risk for smallpox or mpox infection.

Important Safety Information
Warning: Serious Complications
Myocarditis and pericarditis (suspect cases observed at a rate of 5.7 per 1000 primary vaccinees (95% CI: 1.9-13.3)), encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia, generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including STEVENS-JOHNSON SYNDROME), eczema vaccinatum resulting in permanent sequelae or death, accidental eye infection (ocular vaccinia) which can cause ocular complications that may lead to blindness, and fetal death, have occurred following either primary vaccination or revaccination with ACAM2000® or other live vaccinia virus vaccines that were used historically.

Contraindications
Do not administer ACAM2000® to individuals with severe immunodeficiency. These individuals may include persons who are undergoing bone marrow transplantation or persons with primary or acquired immunodeficiency states who require isolation.

Warnings and Precautions
Serious complications that may follow either primary or revaccination with ACAM2000® include myocarditis and/or pericarditis, ischemic heart disease and non-ischemic dilated cardiomyopathy, encephalitis, encephalomyelitis, encephalopathy, progressive vaccinia (vaccinia necrosum), generalized vaccinia, severe vaccinial skin infections, erythema multiforme major (including Stevens-Johnson syndrome), eczema vaccinatum, fetal vaccinia, fetal death, and accidental eye infection (ocular vaccinia) that may lead to blindness. ACAM2000® is a live vaccinia virus that can be transmitted to persons who have close contact with the vaccinee and the risks in contacts are the same as those stated for vaccinees.

Adverse Reactions
Common adverse reactions include inoculation site signs and symptoms, lymphadenitis, and constitutional symptoms, such as malaise, fatigue, fever, myalgia, and headache.
To report Suspected Adverse Reactions, contact Emergent BioSolutions at 1-877-246-8472 (U.S.), 1-800-768-2304 (Canada), or medicalinformation@ebsi.com; or VAERS at 1-800-822-7967 or https://vaers.hhs.gov.

Please see the full Prescribing Information for ACAM2000® for complete Boxed Warning and safety information.

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Safe Harbor Statement 
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the expected timing for delivery of the ACAM2000® vaccine, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements. 

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

¹Smallpox as a Weapon for Bioterrorism

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What contract did Emergent BioSolutions (NYSE:EBS) secure for ACAM2000 on June 29, 2026?

Emergent BioSolutions secured a $52.7 million contract modification to supply ACAM2000® vaccine to ASPR/HHS. According to Emergent, the deal covers vaccine, ancillaries, and diluent replacement lots for U.S. smallpox preparedness.

When will deliveries under Emergent BioSolutions’ new ACAM2000 (EBS) contract begin?

Deliveries under the new ACAM2000® contract modification are expected to begin in June 2026. According to Emergent, shipments will support U.S. smallpox and mpox preparedness and response needs under its existing 10-year ASPR contract.

How does the $52.7 million ACAM2000 contract impact Emergent BioSolutions’ government business?

The $52.7 million modification expands Emergent’s existing 10-year ASPR contract for ACAM2000®. According to Emergent, it reinforces the company’s role as a supplier of medical countermeasures for U.S. biodefense and smallpox and mpox preparedness.

What is ACAM2000 and who is it indicated for, according to Emergent BioSolutions?

ACAM2000® is a live vaccinia virus vaccine for prevention of smallpox and mpox. According to Emergent, it is indicated for individuals determined to be at high risk for smallpox or mpox infection, including specific high-risk adult populations.

What key safety risks are associated with ACAM2000 for Emergent BioSolutions investors to know?

ACAM2000® carries a boxed warning for serious complications, including myocarditis, pericarditis, and encephalitis. According to Emergent, myocarditis and pericarditis were observed at 5.7 per 1000 primary vaccinees, and the live virus can be transmitted to close contacts.

What recent international approvals has ACAM2000 received that may affect Emergent BioSolutions (EBS)?

ACAM2000® was approved in Saudi Arabia for immunization against smallpox and mpox in high-risk individuals. According to Emergent, Singapore also granted an expanded indication for prevention of mpox disease in high-risk adults, potentially supporting broader global use.

Is ACAM2000 suitable for people with weakened immune systems, according to Emergent BioSolutions?

ACAM2000® is not recommended for individuals with severe immunodeficiency. According to Emergent, it should not be administered to people with severe immunodeficiency states, such as certain transplant patients, due to higher risk of serious vaccine-related complications.